Introduction {#section1-2155179019857662}
============

Islet transplantation (IT) is currently offered to a small subset of type 1 diabetes (T1D) patients to replace destroyed beta cells and thereby avoid glycemic lability. IT is a minimally invasive procedure with increasingly better outcome due to progress in the islet isolation technique and immunosuppressive regime^[@bibr1-2155179019857662]^. Allogeneic IT is used for T1D patients, whereas autologous IT is performed in the treatment of chronic pancreatitis or following pancreatectomy^[@bibr2-2155179019857662]^. Both types of transplantation are performed by an injection of islets into the portal vein for engraftment into the liver, which has been the site of choice since the beginning of clinical IT^[@bibr1-2155179019857662],[@bibr3-2155179019857662]^. The outcome of islet autotransplants demonstrate superior long-lasting graft function even if the transplanted islet mass sometimes is lower than in allogeneic transplantations^[@bibr4-2155179019857662]^.

Currently, insulin-independent success rate in allogeneic IT is reported in up to 50% of patients after 5 years^[@bibr1-2155179019857662],[@bibr5-2155179019857662]^. Although some patients revert to exogenous insulin therapy, 87.5% achieved freedom of severe hypoglycemic events 1 year after IT and reported improved quality of life^[@bibr6-2155179019857662]^.

Clinical IT faces two major challenges. First, it is desirable to decrease the need for immunosuppressive treatment in order to expand the group of patients that could be candidates for IT. Second, a lack of donors will arise if the only source of islets comes from brain-dead organ donors. New strategies for beta cell replacement might solve both problems, using encapsulation of insulin-producing cells and stem cells. Promising stem cell programs are developed, but clinical translation of such advanced therapy medicinal products requires safety studies with graft monitoring and retrieval possibilities. Questions regarding the liver as the future implantation site of choice have therefore been raised on several occasions over the last decades. We have previously demonstrated engraftment difficulties after intraportal transplantation, including reduced vasculature, hypoxia, and amyloid formation, which contribute to islet mass reduction and loss of function^[@bibr7-2155179019857662]^. The aim of this commentary is to highlight the conditions of alternative sites for future beta cell replacement.

Advantages of the Intrahepatic Site for Clinical Transplantation {#section2-2155179019857662}
================================================================

The clinical procedure of percutaneous intraportal infusion of islets into the liver is associated with low morbidity and low risk of adverse events, such as bleeding (7%) and portal thrombosis (3.7%)^[@bibr8-2155179019857662]^. In order to further reduce the risk of complications, it is recommended to restrict the total volume of transplanted tissue and to avoid rapid increases in portal pressure^[@bibr9-2155179019857662]^. At the same time, islet volume is a known predictor that positively correlates to transplantation outcome^[@bibr10-2155179019857662]^. A unique consequence of intraportal injection is the scattering of islets throughout hepatic sinusoids, avoiding clusters, which form in every other transplant site and may initially impair diffusion of oxygen and nutrients. On the other hand, this makes the graft very difficult to monitor by imaging techniques, and means that biopsies are difficult to obtain^[@bibr11-2155179019857662]^.

The liver is the main target organ for insulin, and intrahepatic islets can therefore mimic the physiological pancreatic insulin secretion as opposed to systemic insulin release^[@bibr12-2155179019857662]^. In experimental studies, the liver also appears to be more efficient than bone marrow^[@bibr13-2155179019857662]^ and kidney subcapsular site^[@bibr14-2155179019857662]^ due to immunological factors. Islets grafts within the liver lasted a longer time before rejection compared with islet grafts at the kidney subcapsular site in rats^[@bibr13-2155179019857662]^. Likewise, a lower count of recruited lymphocytes has been reported in islet grafts in liver than in islet grafts in bone marrow^[@bibr14-2155179019857662]^.

Challenges with the Intrahepatic Site for Clinical Transplantation {#section3-2155179019857662}
==================================================================

After transplantation, beta cell survival can be impaired by acute and/or chronic factors. Immediately when islets are injected, direct contact with the vascular system exposes them to an instant blood-mediated reaction (IBMIR) which contributes to early graft loss^[@bibr15-2155179019857662][@bibr16-2155179019857662]--[@bibr17-2155179019857662]^. In addition, there is a substantial risk of beta cell death due to acute hypoxia. Even after revascularization, oxygen delivery to intrahepatic islets is inferior compared with native islets in the pancreas, leading to prevailing hypoxia^[@bibr18-2155179019857662][@bibr19-2155179019857662][@bibr20-2155179019857662]--[@bibr21-2155179019857662]^. Better outcomes have been demonstrated with selective transplantation of smaller islets, which exhibit a lower oxygen demand^[@bibr10-2155179019857662]^. Amyloid formation, which is associated with type 2 diabetes, has been found in intraportal islet grafts^[@bibr22-2155179019857662]^. In our recent study, 27% of islets contained amyloid 1 month after transplantation^[@bibr7-2155179019857662]^. Furthermore, gluco-lipotoxicity from surrounding hepatocytes has been shown to damage transplanted islets^[@bibr23-2155179019857662][@bibr24-2155179019857662]--[@bibr25-2155179019857662]^. Although there are controversial findings, Robertson et al. have demonstrated how glycogen metabolism and glucose flux in the hepatic site inhibit secretion of glucagon by transplanted alpha cells, which leads to hyperinsulinemia and hypoglycemia in both autologous and allogeneic settings^[@bibr26-2155179019857662][@bibr27-2155179019857662]--[@bibr28-2155179019857662]^. Kupffer cells are specific to the liver site and have also been shown to be detrimental for islet allograft survival at this site^[@bibr29-2155179019857662]^. Another concern regarding the hepatic site which has been postulated is that portal blood contains potentially harmful concentrations of immunosuppressive agents^[@bibr30-2155179019857662]^. Notably, however, intrahepatic islets only sense to glucose stimulation through the hepatic artery after their revascularization; therefore, the relevance of drug-related effects due to increased concentrations in portal blood can be debated^[@bibr31-2155179019857662]^.

Alternative Implantation Sites and Comparative Studies {#section4-2155179019857662}
======================================================

Comparing engraftment efficacy for different transplant sites is challenging due, for example, to variations in transplanted islet mass, especially when using human islets. [Table 1](#table1-2155179019857662){ref-type="table"} lists experimental studies comparing alternative sites to the liver in the commonly used C57Bl/6 mouse model.

###### 

Experimental Studies Comparing Alternative Islet Transplant Sites to Liver in C57Bl/6 Mice.

![](10.1177_2155179019857662-table1)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (reference)                                          Animal model                Implantation sites                                     Transplant type                                    Islet type                      Islet volume tx                                                            Major outcome                                                                                                                                                                                                      Comments
  ----------------------------------------------------------- --------------------------- ------------------------------------------------------ -------------------------------------------------- ------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------
  Korsgren O et al. 1993^[@bibr32-2155179019857662]^          C57Bl/6                     Liver, spleen and kidney                               Syngeneic                                          Murine                          300 islets                                                                 Better nerve in growth in kidney compared to liver and spleen                                                                                                                                                      Not diabetic recipients

  Lau J et al. 2007^[@bibr33-2155179019857662]^               C57Bl/6 nu/nu and YC-3.0    Pancreas vs. liver                                     Allogeneic to immunodeficient mice                 Murine                          200 islets                                                                 Glucose stimulated insulin release and oxidation rates were markedly decreased in liver                                                                                                                            Intraportally transplanted islets were retrieved after mechanical digestion of liver tissue and picked under a stereomicroscope

  Kim HI et al. 2010^[@bibr34-2155179019857662]^              C57Bl/6                     Kidney, liver, muscle and omentum                      Syngeneic                                          Murine                          Marginal mass (subcurable dose of 100--600 IEQ) calculated for each site   Kidney, liver, muscle, and omentum required 100, 600, 600, 200 islets to cure 50% of engrafted diabetic mice, respectively. Kidney had shortest time to reach euglycemia (3 days), muscle the longest (27 days)\   Different islets volume. High perioperative mortality for liver transplants

  Christoffersson G et al. 2010^[@bibr35-2155179019857662]^   C57Bl/6 and C57Bl/6 nu/nu   Muscle vs. liver                                       Syngeneic and xenogeneic to immunodeficient mice   Human and murine                300 islets                                                                 Improved revascularization and response to glucose challenge in intramuscular transplantation, on par with intrahepatic transplantation                                                                            Vascular density of human islets transplanted to muscle same as murine islets

  Espes D et al. 2016^[@bibr36-2155179019857662]^             C57Bl/6 and C57Bl/6 nu/nu   Omentum vs. liver                                      Syngeneic and xenogeneic to immunodeficient mice   Human and murine                200-300 islets                                                             Normalized vasculature and better response to IVGTT 1-month post-transplant in the omentum                                                                                                                         200 islets not sufficient to restore euglycemia to intraportally transplanted diabetic recipients

  Stokes RA et al. 2017^[@bibr37-2155179019857662]^           C57Bl/6                     Kidney, muscle, liver, spleen capsule, liver capsule   Syngeneic and xenogeneic to immunodeficient mice   Human and murine islets         220-250 islets (syngeneic) and 2000 IEQ human islets                       Kidney best site for murine and human islet transplantation (Kidney used as control).\                                                                                                                             Large transplant volume. Improvement of graft survival when increasing islet number to muscle
                                                                                                                                                                                                                                                                                                               Muscle and intraportal site had similar cure rate for human islets, however both inferior to kidney                                                                                                                

  Cantarelli E et al. 2017^[@bibr13-2155179019857662]^        C57Bl/6 and Balb/c          Bone marrow vs. liver                                  Allogeneic                                         Murine (two different strain)   450 IEQ                                                                    Treating the animals with anti-CD3, islet rejection is prolonged when transplanted to liver compared with bone marrow                                                                                              No difference when no immunosuppressive treatment was given
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**The kidney** subcapsular site appears to provide one of the best engraftment environments, at least for experimentally transplanted islets, and has therefore been used routinely in research. The only clinical trial, however, reports failed graft function despite an increased number of transplanted islets^[@bibr38-2155179019857662]^. Besides the described immunological reasons for failure^[@bibr13-2155179019857662]^, another problem when scaling up to humans is the need of much larger number of islets, which cause clustering in a restricted volume space, thereby impairing the diffusion of oxygen and nutrients to the highly metabolically active tissue. Furthermore, patients with T1D risk developing diabetic nephropathy that could deteriorate the kidney as a possible site.

**The muscle** has, in mice, been demonstrated capable of providing a superior islet revascularization and function when compared with the liver^[@bibr35-2155179019857662]^. Autotransplantation has generated good long-term function in humans^[@bibr35-2155179019857662]^. Meanwhile, clinical allotransplantation has unfortunately terminated in graft loss after 3--4 months^[@bibr39-2155179019857662]^.

**The omentum** appears to provide more rapid revascularization compared with intrahepatic islets^[@bibr36-2155179019857662]^. In humans, patients receiving autologous IT due to chronic pancreatitis have partially been transplanted to the omental pouch, in cases when increased portal pressure prevented complete intraportal transplantation^[@bibr40-2155179019857662]^. However, results are so far disappointing, with only a small number of patients that have been rendered insulin independent, while the majority of grafts have failed. Ongoing clinical trials have reported a functional decline 1 year after transplantation, for unknown reasons^[@bibr41-2155179019857662]^.

**The gastric submucosa**, like the omentum, exhibits favorable portal drainage, and case reports have shown promising results for both types of transplantation^[@bibr42-2155179019857662],[@bibr43-2155179019857662]^.

**The bone marrow** has demonstrated promising results for autotransplantation, in both preclinical^[@bibr44-2155179019857662]^ and clinical studies^[@bibr45-2155179019857662],[@bibr46-2155179019857662]^. However, allogeneic transplantation was not successful, which the authors suspected to be caused by autoimmunity^[@bibr46-2155179019857662]^. A markedly increased destructive inflammatory process occurred in the grafts despite immune suppression of the recipients.

**The spleen** is highly vascularized and has portal drainage. Its immunological function has been assumed advantageous and immune tolerance has been demonstrated in dogs^[@bibr47-2155179019857662]^. The only human trial was marred by splenic infarctions, splenic rupture, and thrombosis^[@bibr48-2155179019857662]^. In Minnesota, there was even one fatal incident following a splenic injection when islets after reflux ended up causing a pulmonary embolism through a porto-systemic anastomosis.

**The anterior chamber of the eye** has, alongside testis, cerebral ventricles, and thymus, been investigated because it is considered "immune privileged." The anterior chamber of the eye has been used for in vivo imaging as well as in large animal models, preceding an ongoing clinical trial (IND017007)^[@bibr49-2155179019857662],[@bibr50-2155179019857662]^.

[Table 2](#table2-2155179019857662){ref-type="table"} gives a summary of alternative sites used in the clinical setting, for both allogeneic and autologous IT.

###### 

Implantation Sites Used in Clinical Allogeneic and Autologous Islet Transplantation.

![](10.1177_2155179019857662-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Transplant site               Transplantation type      Advantages                        Disadvantages                               Comments                                                                                                                                                          References
  ----------------------------- ------------------------- --------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Liver                         Allogeneic & autologous   Low complication rate\            IBMIR\                                      To date, 50--60% of patients reach 3-year post-transplantation insulin independence                                                                               Barton FB et al. 2012^[@bibr1-2155179019857662]^\
                                                          Physiological insulin secretion   Restricted islet volume\                                                                                                                                                                                      Bellin MD et al. 2012^[@bibr5-2155179019857662]^\
                                                                                            Difficult to monitor\                                                                                                                                                                                         Sutherland et al. 2008^[@bibr4-2155179019857662]^
                                                                                            Thrombosis and bleeding adverse effects                                                                                                                                                                       

  Muscle                        Allogeneic & autologous   Minimally invasive\               Systemic insulin release                    Allotransplant clinical trial by Betruzzi demonstrated a decline after 3--4 months in 75% of patients                                                             Betruzzi F et al. 2018^[@bibr39-2155179019857662]^\
                                                          Safe\                                                                                                                                                                                                                                           Rafael E et al. 2008^[@bibr51-2155179019857662]^ Christoffersson G et al. 2010^[@bibr35-2155179019857662]^
                                                          Easy to monitor                                                                                                                                                                                                                                 

  Omentum                       Allogeneic                Minimally invasive\               Few clinical trials                         Transplantation to combined sites. 12--36% of islet volume to omental pouch, rest to liver                                                                        Stice MJ et al. 2018^[@bibr40-2155179019857662]^\
                                                          Portal drainage\                                                                                                                                                                                                                                Baidal DA et al. 2017^[@bibr41-2155179019857662]^
                                                          Retainable graft                                                                                                                                                                                                                                

  Bone marrow                   Allogeneic & autologous   Minimally invasive                Less immunologically favorable vs. liver    Allogeneic transplantation failure                                                                                                                                Maffi P et al. 2013 and 2018^[@bibr45-2155179019857662],[@bibr46-2155179019857662]^

  Gastric submucosa             Allogeneic & autologous   Endoscopic procedure\             Difficulty with monitoring and retrieval?   Case studies. Detectable c-peptide levels 3-year post-autotransplantation to gastric wall. Allotransplant partially to the gastric wall, partially to the liver   Wszola M et al. 2018^[@bibr42-2155179019857662],[@bibr43-2155179019857662]^
                                                          No volume limitation\                                                                                                                                                                                                                           
                                                          Portal drainage                                                                                                                                                                                                                                 

  Kidney                        Allogeneic                Easy access to the graft          Demand large islet volume                   Three patients received islets under kidney capsule, two showed c-peptide production but not sustainable                                                          Jindal RM et al. 1998^[@bibr38-2155179019857662]^

  Spleen                        Autologous                Immunologically favorable         Complications with splenic infarction       Five patients, two received splenic transplantations alone, the other three combined intraportal and splenic                                                      White SA et al. 2000^[@bibr48-2155179019857662]^

  Anterior chamber of the eye   Allogeneic                Immunologically favorable         Tissue volume\                              FDA approval for clinical trial                                                                                                                                   Shishido A et al. 2016^[@bibr52-2155179019857662]^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Concluding Remarks {#section5-2155179019857662}
==================

Many different sites have been evaluated for beta cell replacement in the experimental setting and found superior in different aspects when compared with intraportal IT. Also, in the clinical setting a number of sites have been evaluated, but so far none have reported improved outcome when compared with the intrahepatic site. Even though IT is minimally invasive, especially compared with whole pancreas transplantation, the different sites used are associated with specific technical complications and different volume capacities. Upcoming bioengineering techniques of stem cells and scaffolds, including the use of auxiliary stem cells such as mesenchymal stem cells, neural crest stem cells, or endothelial progenitor cells, may be used to advance the field of beta cell replacement^[@bibr53-2155179019857662][@bibr54-2155179019857662][@bibr55-2155179019857662][@bibr56-2155179019857662]--[@bibr57-2155179019857662]^. However, monitoring possibilities and safety issues make the intrahepatic site inappropriate for this purpose. Changing site could contribute to better graft survival by avoiding, for example, IBMIR and lipotoxicity. However, solutions to obtain scattering of graft tissue are then needed. We consider scattering of the tissue at implantation to be the most important reason why the liver works so well clinically.
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